Measured in a cell proliferation assay using TF-1 human erythroleukemic cells, the EC50 for this effect is less than 0.5 ng/ml.
IL-5 Protein, Human
IL-5 Protein, Human
Price:
Regular price
$240 USD
Regular price
Sale price
$240 USD
Unit price
per
For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details
Product Details
Product Details
Product Specification
| Species | Human |
| Synonyms | IL-5, rRtIL-5, EDF, BCDFII, TRF |
| Accession | P05113 |
| Amino Acid Sequence | Ile20-Ser134 |
| Expression System | E.coli |
| Molecular Weight | 13.3kDa |
| Purity | >95% by SDS-PAGE |
| Endotoxin | <1EU/μg |
| Conjugation | Unconjugated |
| Tag | No Tag |
| Physical Appearance | Lyophilized Powder |
| Storage Buffer | 20mM Tris, pH9.0 |
| Reconstitution | Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation. |
| Stability & Storage |
· 12 months from date of receipt, lyophilized powder stored at -20 to -80℃. · 3 months, -20 to -80℃ under sterile conditions after reconstitution. · 1 week, 2 to 8℃ under sterile conditions after reconstitution. · Please avoid repeated freeze-thaw cycles. |
| Reference |
1、Milburn M V. et al. (1993) A novel dimer configuration revealed by the crystal structure at 2.4 A resolution of human interleukin-5. Nature. 363(6425): 172-176. 2、Woodcock J M. et al. (1994) Three residues in the common beta chain of the human GM-CSF, IL-3 and IL-5 receptors are essential for GM-CSF and IL-5 but not IL-3 high affinity binding and interact with Glu21 of GM-CSF. EMBO J. 13 (21): 5176-85. |
Background
Interleukin 5 (IL-5) is predominantly produced by Th2 cells to regulate differentiation and proliferation of eosinophils. As the major cytokine in eosinophil development, IL-5 induces eosinophil migration, activation, and survival. The primary source of IL-5 is TH2 lymphocytes, but mast cells are also a source in the airways. IL-5 is increased in bronchial biopsies and BAL fluid and serum from symptomatic asthmatic patients, knockout of IL-5 in mice eliminates AHR and eosinophilia, and overexpression or treatment with rIL-5 results in asthma-like lung histopathology. Blockade of IL-5 in humans with mepolizumab, an anti-IL-5 antibody, decreases eosinophils in the sputum and general circulation, and in asthma patients exhibiting hypereosinophilia and resistance to steroid therapy mepolizumab reduces exacerbations.
Picture
Picture
Bioactivity
SDS-PAGE
1μg (R: reducing condition, N: non-reducing condition).
